Gentamicin/vancomycin

Drug Profile

Gentamicin/vancomycin

Alternative Names: DFA-02; Vancomycin/gentamicin

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Dr Reddys Laboratories; Duke Clinical Research Institute
  • Class Aminoglycosides; Antibacterials; Glycopeptides; Peptide antibiotics; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative infections

Most Recent Events

  • 25 Sep 2015 Gentamicin/vancomycin is still in phase-II development for Postoperative infections in USA (Prevention)
  • 01 May 2013 Dr Reddy's Laboratories completes a phase I/II trial in Postoperative infections (Prevention) in the US (NCT01496352)
  • 17 Feb 2012 Phase-I/II clinical trials in Postoperative infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top